Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kristina Bowen

Hematology & Oncology Atlanta, GA Medical Doctor

NPI 1922086784 CMS profile 178270

1100 Johnson Fy Rd Ne Ste 600, Atlanta, GA 30342

Open in the dashboard

General payments

$41,662

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$542 paid to institutions, not to them · program year 2019

Through program year 2025, Kristina Bowen of Atlanta, GA is reported in the CMS Open Payments database as having received $41,662 across 96 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $542 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $735 13
2024 General $568 10
2023 General $2,054 5
2022 General $1,788 4
2021 General $8,472 20
2020 General $14,709 22
2019 General $13,337 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristina Bowen
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Kristina Bowen were reported at $735. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Kristina Bowen Hematology & Oncology median Middle half National median
2019 $13,337 $529 $121–$2,516 $163
2020 $14,709 $339 $82–$2,213 $114
2021 $8,472 $263 $49–$1,965 $132
2022 $1,788 $416 $103–$2,395 $149
2023 $2,054 $542 $125–$2,646 $160
2024 $568 $692 $141–$3,008 $164
2025 $735 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $11,853 32 payments
  2. AstraZeneca Pharmaceuticals LP $10,850 13 payments
  3. Daiichi Sankyo Inc. $9,457 14 payments
  4. Seattle Genetics, Inc. $2,870 3 payments
  5. Gilead Sciences, Inc. $2,100 5 payments
  6. Athenex Pharmaceutical Division, LLC $2,000 1 payment
  7. Novartis Pharmaceuticals Corporation $1,783 4 payments
  8. E.R. Squibb & Sons, L.L.C. $153 1 payment
  9. Janssen Biotech, Inc. $87 4 payments
  10. Exelixis Inc. $82 2 payments
  11. Other $426 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31,690 18 payments
  2. Consulting Fee $5,064 5 payments
  3. Honoraria $2,000 1 payment
  4. Food and Beverage $1,715 52 payments
  5. Travel and Lodging $630 3 payments
  6. Grant $350 1 payment
  7. Education $212 16 payments
Products named General payments · program years 2019–2025
  1. IBRANCE $11,853 32 payments
  2. ENHERTU Oncology $9,353 9 payments
  3. LYNPARZA $7,319 9 payments
  4. TUKYSA $2,892 4 payments
  5. Trodelvy $2,065 3 payments
  6. ENHERTU Oncology $1,943 1 payment
  7. PIQRAY $1,700 1 payment
  8. OPDIVO $153 1 payment
  9. CABOMETYX $82 2 payments
  10. DARZALEX $62 3 payments
  11. Other $680 37 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,384

Median for Hematology-Oncology: 604

Drug cost

$626,289

Median for Hematology-Oncology: $1,306,514

Branded share of claims

9.8%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibrance Palbociclib Brand 37 $585,072
Letrozole Generic 426 $11,234
Tamoxifen Citrate Generic 330 $9,148
Eliquis Apixaban Brand 13 $7,810
Exemestane Generic 39 $5,292
Anastrozole Generic 239 $4,790
Dexamethasone Generic 33 $763
Raloxifene Hcl Generic 27 $694
Citalopram Hbr Citalopram Hydrobromide Brand 55 $285
Ondansetron Hcl Generic 29 $224

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$31,956

Medicare's payments for the services billed

Medicare patients

318

Average age 74

Services billed

561

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 59%
Arthritis 41%
Osteoporosis 26%
Ischemic heart disease 17%
Diabetes 14%
Depression 12%
Atrial fibrillation 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $32
$32 — —
VERZENIO
  • Lilly USA, LLC $28
$28 — —
DARZALEX
  • Janssen Biotech, Inc. $27
$27 — —
TALVEY
  • Janssen Biotech, Inc. $25
$25 — —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record